PKPD Strategies Pharmaceutical Consultant using PKPD modeling and simulation to facilitate discovery-to-clinical transitions and early clinical development of new therapeutics. Having a clear understanding of the relationship between exposure and both on- and off-target effects is increasingly becoming an accepted prerequisite to Phase III clinical development for both small molecule and biologic therapeutics. Obtaining this understanding requires:?      
• a thoughtful strategy interlaced within your nonclinical and clinical development program, ?      
• carefully designed and sequenced nonclinical and clinical studies, and?      
• effective cross-study integration of the results. ?  

PKPD Strategies was formed to assist companies wanting to adopt this proven approach to increasing the success of Phase III development. Please contact me to discuss ways we can work together to make this happen for your drug development program.